Aptinyx Evaluates Strategic Alternatives For Its Future After Failed Trials, 60% Layoffs
Aptinyx Evaluates Strategic Alternatives For Its Future After Failed Trials, 60% Layoffs
Aptinyx 在試驗失敗後評估未來的策略性替代方案，60% 裁員
- In March, Aptinyx Inc (NASDAQ:APTX) completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disorder (PTSD).
- The study was halted in February before its completion to support the company's capital preservation.
- In the analysis, NYX-783 did not demonstrate sufficient improvement on the study's primary endpoint to support the continued advancement of the development program by Aptinyx.
- The company is working with Ladenburg Thalmann as its financial advisor to assist in exploring and evaluating "strategic alternatives."
- In March, Aptinyx reduced its workforce by approximately 60%.
- Aptinyx reported cash and cash equivalents at $56.2 million as of Dec. 31. The company had $25.0 million of debt principal under a capital credit facility with K2 HealthVentures, which remains currently outstanding.
- Last year, the company had another setback when its study in patients with advanced painful diabetic peripheral neuropathy showed its drug couldn't beat the placebo.
- In February, the company announced that its Phase 2 study evaluating the effects of NYX-458 did not demonstrate clinically meaningful improvements over the placebo on the study's efficacy endpoints in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies.
- Price Action: APTX shares are down 4.12% at $0.1280 on the last check Friday.
- 在三月份, 阿普廷尼公司 （NASDAQ：APTX）完成了對在創傷後應激障礙（PTSD）患者（PTSD）的 2B 期 20 毫克臨床研究中註冊的第一 100 名患者的數據的分析。NYX-783
- 該研究在 2 月完成之前暫停，以支持公司的資本保存。
- 在分析中，NYX-783 沒有證明該研究的主要終點有足夠的改進，以支持 Aptinyx 繼續推進開發計劃。
- 該公司正在與拉登堡 Thalmann 合作，擔任其財務顧問，以協助探索和評估「策略性替代方案」。
- 今年 3 月，阿普丁尼減少了約 60％ 的勞動力。
- 截至 12 月 31 日，Aptinyx 報告的現金和現金等價物為 5.62 億美元。該公司在 K2 HealthVentures 的資本信貸融通下擁有 25.0 萬美元的債務本金，目前仍未償還。
- 去年，該公司在晚期糖尿病周圍神經病變患者中的研究顯示其藥物無法擊敗安慰劑時，該公司又遭受了挫折。
- 2 月份，該公司宣布，評估 NYX-458 效果的第二階段研究並未證明該研究對與帕金森氏病和 Lowy 身體癡呆症相關的認知障礙患者的有效性終點在臨床上有意義的改善。
- 價格行動： 在上次檢查週五，APTX 的股票下跌了 4.12%，報 0.1280 美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。